Shipping Address

Pregniforte 30's is a specialized, multi-ingredient fertility support formulation engineered to address female reproductive health challenges, particularly those associated with Polycystic Ovary Syndrome (PCOS), hormonal imbalances, and anovulatory infertility. Available in a pack of 30 tablets (typically structured as 3 blister strips of 10 tablets), this supplement combines clinically studied natural extracts, essential vitamins, and insulin-sensitizing agents to optimize ovarian microenvironments, improve egg (oocyte) quality, and restore regular menstrual cyclicity.

Composition and Active Ingredients

Each Pregniforte tablet contains a synergistic combination of active compounds designed to target reproductive dysfunction at both the hormonal and metabolic levels.

Myo-Inositol (500 mg): A naturally occurring carbocyclic sugar and key second messenger. It plays a critical role in insulin signal transduction and is a crucial constituent of follicular fluid, directly influencing oocyte maturation.

Vitex Agnus-Castus (Chasteberry Extract) (50 mg): A phytotherapeutic agent long utilized to modulate the endocrine system, specifically by targeting the pituitary gland to normalize progesterone and prolactin levels.

Folic Acid (100 mcg): A vital B-vitamin (Vitamin B9) essential for DNA synthesis, rapid cellular division, and the prevention of neural tube defects (NTDs) during early embryonic development.

Fertility Supporting Blend (448 mg): A proprietary combination of micronutrients, amino acids, and botanical extracts designed to minimize oxidative stress, support mitochondrial energy production in developing eggs, and optimize endometrial receptivity.

Pharmacological Mechanisms of Action

Pregniforte targets the root pathophysiological pathways of female infertility through three primary pathways:

Insulin resistance is a hallmark of PCOS, leading to compensatory hyperinsulinemia. Excess insulin acts synergistically with luteinizing hormone (LH) to stimulate the ovarian theca cells, causing them to overproduce androgens (testosterone).

Myo-inositol acts as an intracellular sensitizer for insulin receptors. By restoring normal inositol phosphoglycan ($IPG$) secondary messenger signaling, Pregniforte:

Decreases peripheral insulin resistance.

Lowers circulating insulin levels.

Reduces ovarian androgen synthesis, mitigating clinical symptoms of hyperandrogenism (such as hirsutism and acne).

Vitex works primarily through dopaminergic pathways. Compounds within Vitex bind to dopamine D_2 receptors in the anterior pituitary gland, suppressing the excessive secretion of prolactin. By controlling prolactin and normalizing the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), it:

Restores the balance between luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Promotes a healthy luteal phase by supporting the body's natural progesterone production.

During folliculogenesis, developing oocytes require massive amounts of energy and structural raw materials. The antioxidants within the fertility blend neutralize reactive oxygen species (ROS) in the follicular fluid, protecting egg cell membranes from lipid peroxidation. Folic acid ensures error-free DNA replication during rapid cellular division, lowering the risk of early pregnancy loss.

Clinical Indications

Pregniforte 30's is indicated for women experiencing reproductive difficulties related to:

Polycystic Ovary Syndrome (PCOS): To address insulin resistance, high androgen levels, and associated ovulatory dysfunction.

Anovulation and Oligo-ovulation: To induce regular, predictable ovulatory cycles and restore menstrual regularity.

Suboptimal Egg Quality: Particularly in women of advanced maternal age or those with unexplained infertility.

Assisted Reproductive Technology (ART) Support: To prepare the ovarian microenvironment prior to undergoing Intrauterine Insemination (IUI) or In Vitro Fertilization (IVF), which has been clinically shown to reduce cycle cancellation rates and improve overall pregnancy rates.

Dosage and Administration

To achieve the therapeutic daily threshold of myo-inositol (1500 mg to 2000 mg), the recommended dosing schedule must be followed consistently:

Standard Dosage: Take 1 tablet three times daily or 2 tablets twice daily, preferably after meals to minimize any potential gastrointestinal discomfort.

Administration Timing: For general cycle regulation, Pregniforte is taken daily throughout the menstrual cycle. For targeted ovulation induction protocols under medical guidance, therapy may be initiated on Day 5 of the menstrual cycle for a set duration, often coordinated with timed intercourse or ART procedures.

Duration of Use: Because follicle recruitment and maturation take approximately $90\text{ days}$, a minimum treatment course of 3 consecutive months is highly recommended to see measurable improvements in egg quality and cycle regularity.

Safety, Side Effects, and Contraindications

Pregniforte is generally well-tolerated, but patients should be aware of the following safety profile:

Potential Side Effects: Some patients may experience mild, transient side effects such as abdominal bloating, mild nausea, breast tenderness, or minor mood fluctuations due to shifting hormonal profiles.

Contraindications: Pregniforte should not be taken once a pregnancy is confirmed (unless explicitly directed by an obstetrician). It is contraindicated in patients with severe hepatic or renal impairment.

Drug Interactions: Consult a physician if you are taking concurrent hormonal therapies, oral contraceptives, or medications that modify blood glucose levels (such as metformin), as additive effects may occur.